

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

5'-Substituted 2'-Deoxycytidines as Non-Substrate Inhibitors of Human Deoxycytidine Kinase

K. Krawiec^a; B. Kierdaszuk^b; D. Shugar^{ab}

^a Institute of Biochemistry & Biophysics, Academy of Sciences, Warszawa ^b Department of Biophysics, Institute of Experimental Physics, University of Warsaw, Warszawa, (Poland)

To cite this Article Krawiec, K. , Kierdaszuk, B. and Shugar, D.(1995) '5'-Substituted 2'-Deoxycytidines as Non-Substrate Inhibitors of Human Deoxycytidine Kinase', *Nucleosides, Nucleotides and Nucleic Acids*, 14: 3, 495 — 499

To link to this Article: DOI: 10.1080/15257779508012412

URL: <http://dx.doi.org/10.1080/15257779508012412>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

5'-SUBSTITUTED 2'-DEOXYCYTIDINES AS NON-SUBSTRATE INHIBITORS OF HUMAN DEOXYCYTIDINE KINASE

K. Krawiec,^a B. Kierdaszuk^b and D. Shugar^{a,b *}

^a Institute of Biochemistry & Biophysics, Academy of Sciences, 36 Rakowiecka St., 02-532 Warszawa, and ^b Department of Biophysics, Institute of Experimental Physics, University of Warsaw, 02-089 Warszawa (Poland)

Abstract: Several 5'-substituted analogues of 2'-deoxycytidine (dC), including 5'-amino-2',5'-dideoxycytidine (5'-amino-ddC), 5'-azido-2',5'-dideoxycytidine (5'-azido-ddC) and 5'-O-ethyl-2'-deoxycytidine (5'-O-ethyl-dC), are non-substrate inhibitors of human dC kinase. Whereas 5'-amino-ddC inhibits phosphorylation of deoxyadenosine (dA) with $K_i \sim 1 \mu\text{M}$, inhibition of phosphorylation of dC is bimodal and more effective at low inhibitor concentrations. In particular 5'-O-ethyl-dC inhibits phosphorylation of dA 10-fold more effectively ($K_i \sim 3 \mu\text{M}$) than that of dC ($K_i \sim 30 \mu\text{M}$). For 5'-azido-ddC inhibition was shown directly to be competitive with respect to substrate.

Although considerable effort has been devoted to development of potent selective inhibitors of herpesvirus thymidine kinase (TK),¹ relatively little attention has been paid to inhibitors of cellular nucleoside kinases. One notable exception is adenosine kinase, for which 5'-amino-5'-deoxyadenosine has been reported as a good inhibitor.² It was also long ago shown that 5'-amino-5'-deoxythymidine is a reasonably good inhibitor of mouse ascites carcinoma 180 thymidine kinase.³

During the course of a study on the specificity of human deoxycytidine kinase (dCK), to be elsewhere reported, the foregoing suggested that 5'-amino-2',5'-dideoxycytidine (5'-amino-ddC) might serve as an inhibitor of dCK, the natural substrates of which include also 2'-deoxyadenosine (dA) and 2'-deoxyguanosine. This enzyme is also responsible for "activation" (by phosphorylation) of a number of chemotherapeutically active nucleoside analogues.¹

5'-amino-ddC was prepared by electrochemical reduction, as elsewhere described, of 5'-azido-ddC.⁴ The latter was synthesised according to standard procedures by Dr. K. Felczak, and purified on a silica gel column. The product of reduction, 5'-amino-ddC

TABLE 1

Inhibition of activity of dCK vs dA and dC by 5'-substituted analogues of dC

Inhibitor	pH	IC ₅₀ (μM)		K _i (μM)	
		30 μM dA	1 μM dC	dA	dC
5'-amino-ddC	7.2	2.3 ± 0.2	18 ± 2 ^a	1.3 ± 0.1	3.6 ± 0.6 / 32 ± 3 ^b
	8.6	1.7 ± 0.2	10 ± 1 ^a	1.2 ± 0.2	1.7 ± 0.3 / 32 ± 6 ^b
5'-azido-ddC	7.2	14.0 ± 0.6	104 ± 4	8.0 ± 0.4	60 ± 2
5'-O-methyl-dC	7.2	100 ± 20	500 ± 20	60 ± 15	230 ± 8
5'-O-ethyl-dC	7.2	5.4 ± 0.2	68 ± 2	3.1 ± 0.1	32 ± 1

^a IC₅₀ values measured at 0.4 μM dC.^b The two K_i values were calculated from extrapolated IC₅₀ values for low concentrations of inhibitor (< 2.5 μM) and for the higher concentration range: 5.3 μM and 46 μM at pH 7.2 and 2.3 μM and 41 μM at pH 8.6.

was, in turn, purified by TLC on a cellulose F plate (Merck, Darmstadt) with 1 M ammonium acetate / 96% ethanol (2:5, v/v) ($R_f = 0.57$).

Purified human dCK ⁵ was kindly made available by Dr. S. Eriksson. Potential substrate activity was followed according to standard procedures ⁶ with the use of [γ -³²P] ATP (0.7 mCi/mmol) as phosphate donor. Inhibitory activity was measured with use of cold Mg·ATP as phosphate donor and ³H-labeled dC and dA (15–45 Ci/mmol) as acceptors at concentrations of 1 μM and 30 μM, respectively (hence close to their measured K_m values of 0.9 μM and 40 μM at pH 7.2, and 1.5 μM and 70 μM at pH 8.6).

Bearing in mind that 5'-amino-5'-deoxythymidine is a substrate for the TK of herpes simplex virus type 1,⁷ it was first established that 5'-amino-ddC is not a substrate for dCK. Following the observation that 5'-azido-ddC exhibits inhibitory properties (see below), this compound was also shown not to be a substrate and, in turn, prompted us to examine 5'-O-methyl-dC and 5'-O-ethyl-dC, kindly prepared by Dr. Z. Kazimierczuk, and the syntheses of which will be described elsewhere.

The inhibitory properties of the foregoing compounds were initially expressed in terms of their IC₅₀ values, the concentration giving half-maximal inhibition.




FIG. 1

Inhibition of activity of dCK with dC as substrate by 5'-amino-ddC. Rates are normalised to the uninhibited rate, taken as 1.0. Insert: Same data in the form of a Dixon plot.

Subsequently, the type of inhibition exhibited by 5'-azido-ddC was directly established as competitive with respect to dC. Assuming that the other inhibitors were also competitive, their K_i values were calculated from the relationship

$$K_i = IC_{50} \times K_m / ([S]_0 + K_m)$$

where $[S]_0$ is the substrate concentration at the measured value of IC_{50} , and the K_m values are Michaelis constants (listed above).

The IC_{50} values, and the measured or calculated K_i s, with dC or dA as substrates, are listed in Table 1.

It will be noted that, with dA as a substrate, the lead compound 5'-amino-ddC is an effective inhibitor, with $K_i \sim 1 \mu\text{M}$. By contrast, the same compound inhibited phosphorylation of dC effectively only at low inhibitor concentrations ($< 2.5 \mu\text{M}$); at higher concentrations it was 10-fold less effective. This bimodal inhibitory activity (see Fig. 1) was exhibited only by 5'-amino-ddC with dC as a substrate, and the resulting calculated K_i values, based on extrapolated values of IC_{50} at low ($< 2.5 \mu\text{M}$) and high ($> 2.5 \mu\text{M}$) inhibitor concentrations, must be considered as only rough approximations.

Inhibition by 5'-amino-ddC was measured at both pH 7.2 and 8.6 because of the previous demonstration that 5'-amino-5'-deoxyadenosine at neutral pH is protonated at the 5'-amino group ($\text{pK}_a \sim 8.5$), and is a much better inhibitor of adenosine kinase at more alkaline pH, where there is a preponderance of the neutral form. However, at pH 8.6, 5'-amino-ddC was only 2-fold more active vs dC, but not dA, and only in the low inhibitor concentration range (Fig. 1 and Table 1). This complex behaviour may be related to the known high negative cooperativity of the enzyme,^{5,8} and is being further investigated. It remains to note that the specificity of 5'-amino-ddC as an inhibitor of dCK is further underlined by the fact that the corresponding 5'-amino-ddU was found not to be a significant inhibitor.

From Table 1 it will be seen that 5'-azido-ddC is a reasonably good and better inhibitor of phosphorylation of dA than of dC. In this case the K_i value vs dC was obtained directly with the aid of Dixon plots, demonstrating that inhibition was competitive. By contrast, 5'-O-methyl-dC is a much poorer inhibitor. Replacement of the methyl group by an ethyl strikingly enhanced inhibitory activity, leading to a K_i of $3.1 \mu\text{M}$ with dA as a substrate and $32 \mu\text{M}$ with dC. The 10-fold difference in K_i values points to the utility of 5'-O-ethyl-dC as a tool for following the intracellular effects of phosphorylation of dC with concomitant marked inhibition of phosphorylation of dA.

The foregoing results suggest that larger and/or bulkier hydrophobic 5'-substituents may lead to more specific and potent inhibitors (*cf.* ⁹). It is also worth noting that 5'-azido-ddC, with a K_i of $8 \mu\text{M}$ for phosphorylation of dA, may prove to be a useful photoaffinity label for dCK.

Finally, in the light of reports on elevated dCK activity in tumor cells, the above non-substrate inhibitors may prove useful in combination chemotherapy.¹⁰

Acknowledgments: Supported by the Committee for Scientific Research, KBN grants No. 6 P 203 046 05 and 6 62539203 p/01.

REFERENCES

1. Shugar, D. *Molecular Aspects of Chemotherapy* (D. Shugar, W. Rode & E. Borowski, eds.), pp. 239-271. Springer Verlag, Berlin and PWN, Warsaw (1992).

2. Miller, R. L., Adamczyk, D. L., Miller, W. H., Koszalka, G. W., Rideout, J. L., Beacham, L. M. III, Chao, E. Y., Haggerty, J. J., Krenitsky, T. A. & Elion, G. B. *J. Biol. Chem.* **254**: 2346-2352 (1979).
3. Cheng, Y. C. & Prusoff, W. H. *Biochemistry* **13**: 1179-1185 (1974).
4. Kawczyński, W., Czocharalska, B. & Shugar, D. *Acta Biochim. Pol.* **40**: 214-223 (1993).
5. Bohman, C. & Eriksson, S. *Biochemistry* **27**, 4258-4265 (1988).
6. Eriksson, S., Kierdaszuk, B., Munch-Petersen, B., Öberg, B. & Johansson, N. G. *Biochem. Biophys. Res. Commun.* **176**: 586-592 (1991).
7. Chen, M. S., Shiau, G. T. & Prusoff, W. H. *Antimicrob. Ag. Chemother.* **18**: 433-436 (1980).
8. Durham, J. P. & Ives, D. H. *J. Biol. Chem.* **45**: 2276-2284 (1970).
9. Krenitsky, T. A., Tuttle, J. V., Koszalka, G. W., Chen, I. S., Beacham, L. M. III, Rideout, J. L., & Elion, G. B. *J. Biol. Chem.* **251**: 4055-4061 (1976).
10. Weber, G., Signal, R. L., Yeh, Y., A. & Szekres, T. *Oncol. Res.* **4**: 517-522 (1992).